Cytokine & Growth Factor Reviews
Volume 21, Issue 4 , Pages 275-286 , August 2010

Crosstalk between TNF and glucocorticoid receptor signaling pathways

  • Tom Van Bogaert

      Affiliations

    • Department of Biomedical Molecular Biology, Ghent University, Belgium
    • Department for Molecular Biomedical Research, VIB, Ghent, Belgium
    • ,
  • Karolien De Bosscher

      Affiliations

    • Laboratory for Eukaryotic Gene Expression and Signal Transduction (LEGEST), Department of Physiology, Ghent University, Belgium
    • ,
  • Claude Libert

      Affiliations

    • Department of Biomedical Molecular Biology, Ghent University, Belgium
    • Department for Molecular Biomedical Research, VIB, Ghent, Belgium
    • Corresponding Author InformationCorresponding author at: DMBR, Technologypark, 927, 9052 Ghent, Belgium. Tel.: +32 9 3313700.

References 

  1. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proceedings of the National Academy of Sciences of the United States of America. 1975;72(9):3666–3670
  2. Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. The New England Journal of Medicine. 2006;354(7):697–708
  3. Kollias G, Douni E, Kassiotis G, Kontoyiannis D. The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Annals of the Rheumatic Diseases. 1999;58(Suppl. 1):I32–I39
  4. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity. 1999;10(3):387–398
  5. Brouckaert PG, Leroux-Roels GG, Guisez Y, Tavernier J, Fiers W. In vivo anti-tumour activity of recombinant human and murine TNF, alone and in combination with murine IFN-gamma, on a syngeneic murine melanoma. International Journal of Cancer. 1986;38(5):763–769
  6. Eggermont AM, ten Hagen TL. Isolated limb perfusion for extremity softtissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives. Current Oncology Reports. 2001;3(4):359–367
  7. Balkwill F. Tumour necrosis factor and cancer. Nature Reviews. 2009;9(5):361–371
  8. Li H, Lin X. Positive and negative signaling components involved in TNFalpha-induced NF-kappaB activation. Cytokine. 2008;41(1):1–8
  9. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. The New England Journal of Medicine. 1995;332(20):1351–1362
  10. McCann SM, Lyson K, Karanth S, Gimeno M, Belova N, Kamat A, et al. Mechanism of action of cytokines to induce the pattern of pituitary hormone secretion in infection. Annals of the New York Academy of Sciences. 1995;771:386–395
  11. De Bosscher K, Haegeman G. Minireview: latest perspectives on antiinflammatory actions of glucocorticoids. Molecular Endocrinology (Baltimore, MD). 2009;23(3):281–291
  12. Chrousos GP, Kino T. Intracellular glucocorticoid signaling: a formerly simple system turns stochastic. Science's STKE. 2005;2005(304):pe48
  13. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. The New England Journal of Medicine. 2005;353(16):1711–1723
  14. McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-associated adverse events. Current Opinion in Rheumatology. 2008;20(2):131–137
  15. Franchimont D, Martens H, Hagelstein MT, Louis E, Dewe W, Chrousos GP, et al. Tumor necrosis factor alpha decreases, and interleukin-10 increases, the sensitivity of human monocytes to dexamethasone: potential regulation of the glucocorticoid receptor. The Journal of Clinical Endocrinology and Metabolism. 1999;84(8):2834–2839
  16. Webster JC, Oakley RH, Jewell CM, Cidlowski JA. Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta isoform: a mechanism for the generation of glucocorticoid resistance. Proceedings of the National Academy of Sciences of the United States of America. 2001;98(12):6865–6870
  17. Leung DY, Hamid Q, Vottero A, Szefler SJ, Surs W, Minshall E, et al. Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta. The Journal of Experimental Medicine. 1997;186(9):1567–1574
  18. Miller AH, Pariante CM, Pearce BD. Effects of cytokines on glucocorticoid receptor expression and function. Glucocorticoid resistance and relevance to depression. Advances in Experimental Medicine and Biology. 1999;461:107–116
  19. Mannel DN, Echtenacher B. TNF in the inflammatory response. Chemical Immunology. 2000;74:141–161
  20. Sherman ML, Spriggs DR, Arthur KA, Imamura K, Frei E, Kufe DW. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. Journal of Clinical Oncology. 1988;6(2):344–350
  21. Saks S, Rosenblum M. Recombinant human TNF-alpha: preclinical studies and results from early clinical trials. Immunology Series. 1992;56:567–587
  22. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, et al. Shock and tissue injury induced by recombinant human cachectin. Science (New York, NY). 1986;234(4775):470–474
  23. Kettelhut IC, Fiers W, Goldberg AL. The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors. Proceedings of the National Academy of Sciences of the United States of America. 1987;84(12):4273–4277
  24. Libert C, Van Bladel S, Brouckaert P, Fiers W. The influence of modulating substances on tumor necrosis factor and interleukin-6 levels after injection of murine tumor necrosis factor or lipopolysaccharide in mice. Journal of Immunotherapy. 1991;10(4):227–235
  25. Bertini R, Bianchi M, Ghezzi P. Adrenalectomy sensitizes mice to the lethal effects of interleukin 1 and tumor necrosis factor. The Journal of Experimental Medicine. 1988;167(5):1708–1712
  26. Brouckaert P, Everaerdt B, Fiers W. The glucocorticoid antagonist 38486RU mimics interleukin-1 in its sensitization to the lethal and interleukin-6-inducing properties of tumor necrosis factor. European Journal of Immunology. 1992;22(4):981–986
  27. Bantel H, Schmitz ML, Raible A, Gregor M, Schulze-Osthoff K. Critical role of NF-kappaB and stress-activated protein kinases in steroid unresponsiveness. The FASEB Journal. 2002;16(13):1832–1834
  28. Cho YS, Kim TB, Lee TH, Moon KA, Lee J, Kim YK, et al. Chlamydia pneumoniae infection enhances cellular proliferation and reduces steroid responsiveness of human peripheral blood mononuclear cells via a tumor necrosis factor-alpha-dependent pathway. Clinical and Experimental Allergy. 2005;35(12):1625–1631
  29. Cucchiara S, Latiano A, Palmieri O, Canani RB, D’Inca R, Guariso G, et al. Polymorphisms of tumor necrosis factor-alpha but not MDR1 influence response to medical therapy in pediatric-onset inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition. 2007;44(2):171–179
  30. Tripathi G, Jafar T, Mandal K, Mahdi AA, Awasthi S, Sharma RK, et al. Does cytokine gene polymorphism affect steroid responses in idiopathic nephrotic syndrome?. Indian Journal of Medical Sciences. 2008;62(10):383–391
  31. Baumann H, Gauldie J. The acute phase response. Immunology Today. 1994;15(2):74–80
  32. Libert C, Brouckaert P, Shaw A, Fiers W. Induction of interleukin 6 by human and murine recombinant interleukin 1 in mice. European Journal of Immunology. 1990;20(3):691–694
  33. Thorn CF, Whitehead AS. Differential glucocorticoid enhancement of the cytokine-driven transcriptional activation of the human acute phase serum amyloid A genes, SAA1 and SAA2. Journal of Immunology (Baltimore, MD). 2002;169(1):399–406
  34. Asselta R, Duga S, Modugno M, Malcovati M, Tenchini ML. Identification of a glucocorticoid response element in the human gamma chain fibrinogen promoter. Thrombosis and Haemostasis. 1998;79(6):1144–1150
  35. Shimoishi K, Kai H, Kabu K, Komori T, Maruyama T, Otagiri M. FK506 (tacrolimus) increases rat alpha1-acid glycoprotein expression in liver and primary cultured hepatocytes. European Journal of Pharmacology. 2001;420(2–3):91–95
  36. Libert C, Brouckaert P, Fiers W. Protection by alpha 1-acid glycoprotein against tumor necrosis factor-induced lethality. The Journal of Experimental Medicine. 1994;180(4):1571–1575
  37. Libert C, Van Molle W, Brouckaert P, Fiers W. alpha1-Antitrypsin inhibits the lethal response to TNF in mice. Journal of Immunology (Baltimore, MD). 1996;157(11):5126–5129
  38. Bergann T, Zeissig S, Fromm A, Richter JF, Fromm M, Schulzke JD. Glucocorticoids and tumor necrosis factor-alpha synergize to induce absorption by the epithelial sodium channel in the colon. Gastroenterology. 2009;136(3):933–942
  39. Hermoso MA, Matsuguchi T, Smoak K, Cidlowski JA. Glucocorticoids and tumor necrosis factor alpha cooperatively regulate toll-like receptor 2 gene expression. Molecular and Cellular Biology. 2004;24(11):4743–4756
  40. Webster JC, Huber RM, Hanson RL, Collier PM, Haws TF, Mills JK, et al. Dexamethasone and tumor necrosis factor-alpha act together to induce the cellular inhibitor of apoptosis-2 gene and prevent apoptosis in a variety of cell types. Endocrinology. 2002;143(10):3866–3874
  41. De Bosscher K, Vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocrine Reviews. 2003;24(4):488–522
  42. Liberman AC, Druker J, Perone MJ, Arzt E. Glucocorticoids in the regulation of transcription factors that control cytokine synthesis. Cytokine & Growth Factor Reviews. 2007;18(1–2):45–56
  43. De Bosscher K, Vanden Berghe W, Haegeman G. Cross-talk between nuclear receptors and nuclear factor kappaB. Oncogene. 2006;25(51):6868–6886
  44. Schoneveld OJ, Gaemers IC, Lamers WH. Mechanisms of glucocorticoid signalling. Biochimica et Biophysica Acta. 2004;1680(2):114–128
  45. Jenkins BD, Pullen CB, Darimont BD. Novel glucocorticoid receptor coactivator effector mechanisms. Trends in Endocrinology and Metabolism. 2001;12(3):122–126
  46. Schaaf MJ, Cidlowski JA. Molecular mechanisms of glucocorticoid action and resistance. The Journal of Steroid Biochemistry and Molecular Biology. 2002;83(1–5):37–48
  47. Mukaida N, Morita M, Ishikawa Y, Rice N, Okamoto S, Kasahara T, et al. Novel mechanism of glucocorticoid-mediated gene repression. Nuclear factor-kappa B is target for glucocorticoid-mediated interleukin 8 gene repression. The Journal of Biological Chemistry. 1994;269(18):13289–13295
  48. Ray A, Prefontaine KE. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proceedings of the National Academy of Sciences of the United States of America. 1994;91(2):752–756
  49. Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA, Baldwin AS. Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. Molecular and Cellular Biology. 1995;15(2):943–953
  50. Jonat C, Rahmsdorf HJ, Park KK, Cato AC, Gebel S, Ponta H, et al. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell. 1990;62(6):1189–1204
  51. Schule R, Rangarajan P, Kliewer S, Ransone LJ, Bolado J, Yang N, et al. Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell. 1990;62(6):1217–1226
  52. Tuckermann JP, Reichardt HM, Arribas R, Richter KH, Schutz G, Angel P. The DNA binding-independent function of the glucocorticoid receptor mediates repression of AP-1-dependent genes in skin. The Journal of Cell Biology. 1999;147(7):1365–1370
  53. Yang-Yen HF, Chambard JC, Sun YL, Smeal T, Schmidt TJ, Drouin J, et al. Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein–protein interaction. Cell. 1990;62(6):1205–1215
  54. Kassel O, Herrlich P. Crosstalk between the glucocorticoid receptor and other transcription factors: molecular aspects. Molecular and Cellular Endocrinology. 2007;275(1–2):13–29
  55. Smoak KA, Cidlowski JA. Mechanisms of glucocorticoid receptor signaling during inflammation. Mechanisms of Ageing and Development. 2004;125(10–11):697–706
  56. Dong C, Davis RJ, Flavell RA. MAP kinases in the immune response. Annual Review of Immunology. 2002;20:55–72
  57. Sandler H, Stoecklin G. Control of mRNA decay by phosphorylation of tristetraprolin. Biochemical Society Transactions. 2008;36(Pt 3):491–496
  58. Ono K, Han J. The p38 signal transduction pathway: activation and function. Cellular Signalling. 2000;12(1):1–13
  59. Treisman R. Regulation of transcription by MAP kinase cascades. Current Opinion in Cell Biology. 1996;8(2):205–215
  60. Vanden Berghe W, Plaisance S, Boone E, De Bosscher K, Schmitz ML, Fiers W, et al. p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factorkappaB p65 transactivation mediated by tumor necrosis factor. The Journal of Biological Chemistry. 1998;273(6):3285–3290
  61. Vermeulen L, De Wilde G, Van Damme P, Vanden Berghe W, Haegeman G. Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). The EMBO Journal. 2003;22(6):1313–1324
  62. Williams LM, Lali F, Willetts K, Balague C, Godessart N, Brennan F, et al. Rac mediates TNF-induced cytokine production via modulation of NF-kappaB. Molecular Immunology. 2008;45(9):2446–2454
  63. Westwick JK, Weitzel C, Minden A, Karin M, Brenner DA. Tumor necrosis factor alpha stimulates AP-1 activity through prolonged activation of the c-Jun kinase. The Journal of Biological Chemistry. 1994;269(42):26396–26401
  64. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. The Journal of Biological Chemistry. 1995;270(28):16483–16486
  65. King EM, Holden NS, Gong W, Rider CF, Newton R. Inhibition of NF-κB-dependent transcription by MKP-1: transcriptional repression by glucocorticoids occurring via p38 MAPK. The Journal of Biological Chemistry. 2009;
  66. Lasa M, Abraham SM, Boucheron C, Saklatvala J, Clark AR. Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Molecular and Cellular Biology. 2002;22(22):7802–7811
  67. Li L, Chen SF, Liu Y. MAP kinase phosphatase-1, a critical negative regulator of the innate immune response. International Journal of Clinical and Experimental Medicine. 2009;2(1):48–67
  68. Horsch K, de Wet H, Schuurmans MM, Allie-Reid F, Cato AC, Cunningham J, et al. Mitogen-activated protein kinase phosphatase 1/dual specificity phosphatase 1 mediates glucocorticoid inhibition of osteoblast proliferation. Molecular Endocrinology (Baltimore, MD). 2007;21(12):2929–2940
  69. Ventura JJ, Roncero C, Fabregat I, Benito M. Glucocorticoid receptor down-regulates c-Jun amino terminal kinases induced by tumor necrosis factor alpha in fetal rat hepatocyte primary cultures. Hepatology (Baltimore, MD). 1999;29(3):849–857
  70. Gonzalez MV, Jimenez B, Berciano MT, Gonzalez-Sancho JM, Caelles C, Lafarga M, et al. Glucocorticoids antagonize AP-1 by inhibiting the Activation/phosphorylation of JNK without affecting its subcellular distribution. The Journal of Cell Biology. 2000;150(5):1199–1208
  71. Bruna A, Nicolas M, Munoz A, Kyriakis JM, Caelles C. Glucocorticoid receptor-JNK interaction mediates inhibition of the JNK pathway by glucocorticoids. The EMBO Journal. 2003;22(22):6035–6044
  72. Cissel DS, Beaven MA. Disruption of Raf-1/heat shock protein 90 complex and Raf signaling by dexamethasone in mast cells. The Journal of Biological Chemistry. 2000;275(10):7066–7070
  73. Xu J, Li Q. Review of the in vivo functions of the p160 steroid receptor coactivator family. Molecular Endocrinology (Baltimore, MD). 2003;17(9):1681–1692
  74. Werbajh S, Nojek I, Lanz R, Costas MA. RAC-3 is a NF-kappa B coactivator. FEBS Letters. 2000;485(2–3):195–199
  75. Sheppard KA, Phelps KM, Williams AJ, Thanos D, Glass CK, Rosenfeld MG, et al. Nuclear integration of glucocorticoid receptor and nuclear factor-kappaB signaling by CREB-binding protein and steroid receptor coactivator-1. The Journal of Biological Chemistry. 1998;273(45):29291–29294
  76. De Bosscher K, Vanden Berghe W, Vermeulen L, Plaisance S, Boone E, Haegeman G. Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proceedings of the National Academy of Sciences of the United States of America. 2000;97(8):3919–3924
  77. De Bosscher K, Vanden Berghe W, Haegeman G. Glucocorticoid repression of AP-1 is not mediated by competition for nuclear coactivators. Molecular Endocrinology (Baltimore, MD). 2001;15(2):219–227
  78. Wu J, Li Y, Dietz J, Lala DS. Repression of p65 transcriptional activation by the glucocorticoid receptor in the absence of receptor-coactivator interactions. Molecular Endocrinology (Baltimore, MD). 2004;18(1):53–62
  79. Coghlan MJ, Jacobson PB, Lane B, Nakane M, Lin CW, Elmore SW, et al. A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects. Molecular Endocrinology (Baltimore, MD). 2003;17(5):860–869
  80. Rogatsky I, Luecke HF, Leitman DC, Yamamoto KR. Alternate surfaces of transcriptional coregulator GRIP1 function in different glucocorticoid receptor activation and repression contexts. Proceedings of the National Academy of Sciences of the United States of America. 2002;99(26):16701–16706
  81. Nissen RM, Yamamoto KR. The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes & Development. 2000;14(18):2314–2329
  82. Luecke HF, Yamamoto KR. The glucocorticoid receptor blocks P-TEFb recruitment by NFkappaB to effect promoter-specific transcriptional repression. Genes & Development. 2005;19(9):1116–1127
  83. Beck IM, Vanden Berghe W, Vermeulen L, Bougarne N, Vander Cruyssen B, Haegeman G, et al. Altered subcellular distribution of MSK1 induced by glucocorticoids contributes to NF-kappaB inhibition. The EMBO Journal. 2008;27(12):1682–1693
  84. Deak M, Clifton AD, Lucocq LM, Alessi DR. Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB. The EMBO Journal. 1998;17(15):4426–4441
  85. Barnes PJ. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. British Journal of Pharmacology. 2006;148(3):245–254
  86. Ito K, Barnes PJ, Adcock IM. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12. Molecular and Cellular Biology. 2000;20(18):6891–6903
  87. Ito K, Lim S, Caramori G, Chung KF, Barnes PJ, Adcock IM. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. The FASEB Journal. 2001;15(6):1110–1112
  88. Tsaprouni LG, Ito K, Punchard N, Adcock IM. Triamcinolone acetonide and dexamethasome suppress TNF-alpha-induced histone H4 acetylation on lysine residues 8 and 12 in mononuclear cells. Annals of the New York Academy of Sciences. 2002;973:481–483
  89. Clark AR. Anti-inflammatory functions of glucocorticoid-induced genes. Molecular and Cellular Endocrinology. 2007;275(1–2):79–97
  90. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NFkappa B activity through induction of I kappa B synthesis. Science (New York, NY). 1995;270(5234):286–290
  91. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science (New York, NY). 1995;270(5234):283–286
  92. Adcock IM, Nasuhara Y, Stevens DA, Barnes PJ. Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targetting of NF-kappaB and lack of I-kappaB involvement. British Journal of Pharmacology. 1999;127(4):1003–1011
  93. Adcock IM, Newton R, Barnes PJ. NF-kappa B involvement in IL-1 betainduction of GM-CSF and COX-2: inhibition by glucocorticoids does not require I-kappa B. Biochemical Society Transactions. 1997;25(2):154S
  94. De Bosscher K, Schmitz ML, Vanden Berghe W, Plaisance S, Fiers W, Haegeman G. Glucocorticoid-mediated repression of nuclear factorkappaB-dependent transcription involves direct interference with transactivation. Proceedings of the National Academy of Sciences of the United States of America. 1997;94(25):13504–13509
  95. Heck S, Bender K, Kullmann M, Gottlicher M, Herrlich P, Cato AC. I kappaB alpha-independent downregulation of NF-kappaB activity by glucocorticoid receptor. The EMBO Journal. 1997;16(15):4698–4707
  96. De Bosscher K, Vanden Berghe W, Beck IM, Van Molle W, Hennuyer N, Hapgood J, et al. A fully dissociated compound of plant origin for inflammatory gene repression. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(44):15827–15832
  97. Dewint P, Gossye V, De Bosscher K, Vanden Berghe W, Van Beneden K, Deforce D, et al. A plant-derived ligand favoring monomeric glucocorticoid receptor conformation with impaired transactivation potential attenuates collagen-induced arthritis. Journal of Immunology (Baltimore, MD). 2008;180(4):2608–2615
  98. van Loo G, Sze M, Bougarne N, Praet J, Mc Guire C, Ullrich A, et al. Antiinflammatory properties of a plant-derived nonsteroidal, dissociated glucocorticoid receptor modulator in experimental autoimmune encephalomyelitis. Molecular Endocrinology (Baltimore, MD). 2010;24(2):310–322
  99. Ayroldi E, Riccardi C. Glucocorticoid-induced leucine zipper (GILZ): a new important mediator of glucocorticoid action. The FASEB Journal. 2009;
  100. Smoak K, Cidlowski JA. Glucocorticoids regulate tristetraprolin synthesis and posttranscriptionally regulate tumor necrosis factor alpha inflammatory signaling. Molecular and Cellular Biology. 2006;26(23):9126–9135
  101. Carballo E, Lai WS, Blackshear PJ. Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science (New York, NY). 1998;281(5379):1001–1005
  102. Carrick DM, Lai WS, Blackshear PJ. The tandem CCCH zinc finger protein tristetraprolin and its relevance to cytokine mRNA turnover and arthritis. Arthritis Research & Therapy. 2004;6(6):248–264
  103. Ishmael FT, Fang X, Galdiero MR, Atasoy U, Rigby WF, Gorospe M, et al. Role of the RNA-binding protein tristetraprolin in glucocorticoid-mediated gene regulation. Journal of Immunology (Baltimore, MD). 2008;180(12):8342–8353
  104. Caldenhoven E, Liden J, Wissink S, Van de Stolpe A, Raaijmakers J, Koenderman L, et al. Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids. Molecular Endocrinology (Baltimore, MD). 1995;9(4):401–412
  105. McKay LI, Cidlowski JA. Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor signaling pathways. Endocrine Reviews. 1999;20(4):435–459
  106. McKay LI, Cidlowski JA. Cross-talk between nuclear factor-kappa B and the steroid hormone receptors: mechanisms of mutual antagonism. Molecular Endocrinology (Baltimore, MD). 1998;12(1):45–56
  107. Tliba O, Damera G, Banerjee A, Gu S, Baidouri H, Keslacy S, et al. Cytokines induce an early steroid resistance in airway smooth muscle cells: novel role of interferon regulatory factor-1. American Journal of Respiratory Cell and Molecular Biology. 2008;38(4):463–472
  108. Yarilina A, Park-Min KH, Antoniv T, Hu X, Ivashkiv LB. TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon response genes. Nature Immunology. 2008;9(4):378–387
  109. Bhandare R, Damera G, Banerjee A, Flammer JR, Keslacy S, Rogatsky I, et al. Glucocorticoid receptor interacting protein-1 restores glucocorticoid responsiveness in steroid-resistant airway structural cells. American Journal of Respiratory Cell and Molecular Biology. 2009;
  110. Kino T, Chrousos GP. Tumor necrosis factor alpha receptor- and Fas associated FLASH inhibit transcriptional activity of the glucocorticoid receptor by binding to and interfering with its interaction with p160 type nuclear receptor coactivators. The Journal of Biological Chemistry. 2003;278(5):3023–3029
  111. Kino T, Ichijo T, Chrousos GP. FLASH interacts with p160 coactivator subtypes and differentially suppresses transcriptional activity of steroid hormone receptors. The Journal of Steroid Biochemistry and Molecular Biology. 2004;92(5):357–363
  112. Leite RS, Brown AG, Strauss JF. Tumor necrosis factor-alpha suppresses the expression of steroid receptor coactivator-1 and -2: a possible mechanism contributing to changes in steroid hormone responsiveness. The FASEB Journal. 2004;18(12):1418–1420
  113. Kim MS, Sweeney TR, Shigenaga JK, Chui LG, Moser A, Grunfeld C, et al. Tumor necrosis factor and interleukin 1 decrease RXRalpha, PPARalpha, PPARgamma, LXRalpha, and the coactivators SRC-1, PGC-1alpha, and PGC-1beta in liver cells. Metabolism: Clinical and Experimental. 2007;56(2):267–279
  114. Wang Y, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. Downregulation of liver X receptor-alpha in mouse kidney and HK-2 proximal tubular cells by LPS and cytokines. Journal of Lipid Research. 2005;46(11):2377–2387
  115. Beck IM, Vanden Berghe W, Vermeulen L, Yamamoto KR, Haegeman G, De Bosscher K. Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases. Endocrine Reviews. 2009;
  116. Galliher-Beckley AJ, Williams JG, Collins JB, Cidlowski JA. Glycogen synthase kinase 3beta-mediated serine phosphorylation of the human glucocorticoid receptor redirects gene expression profiles. Molecular and Cellular Biology. 2008;28(24):7309–7322
  117. Webster JC, Jewell CM, Bodwell JE, Munck A, Sar M, Cidlowski JA. Mouse glucocorticoid receptor phosphorylation status influences multiple functions of the receptor protein. The Journal of Biological Chemistry. 1997;272(14):9287–9293
  118. Bodwell JE, Hu JM, Orti E, Munck A. Hormone-induced hyperphosphorylation of specific phosphorylated sites in the mouse glucocorticoid receptor. The Journal of Steroid Biochemistry and Molecular Biology. 1995;52(2):135–140
  119. Bodwell JE, Orti E, Coull JM, Pappin DJ, Smith LI, Swift F. Identification of phosphorylated sites in the mouse glucocorticoid receptor. The Journal of Biological Chemistry. 1991;266(12):7549–7555
  120. Ismaili N, Garabedian MJ. Modulation of glucocorticoid receptor function via phosphorylation. Annals of the New York Academy of Sciences. 2004;1024:86–101
  121. Wang Z, Frederick J, Garabedian MJ. Deciphering the phosphorylation “code” of the glucocorticoid receptor in vivo. The Journal of Biological Chemistry. 2002;277(29):26573–26580
  122. Dephoure N, Zhou C, Villen J, Beausoleil SA, Bakalarski CE, Elledge SJ, et al. A quantitative atlas of mitotic phosphorylation. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(31):10762–10767
  123. Rogatsky I, Logan SK, Garabedian MJ. Antagonism of glucocorticoid receptor transcriptional activation by the c-Jun N-terminal kinase. Proceedings of the National Academy of Sciences of the United States of America. 1998;95(5):2050–2055
  124. Szatmary Z, Garabedian MJ, Vilcek J. Inhibition of glucocorticoid receptor-mediated transcriptional activation by p38 mitogen-activated protein (MAP) kinase. The Journal of Biological Chemistry. 2004;279(42):43708–43715
  125. Itoh M, Adachi M, Yasui H, Takekawa M, Tanaka H, Imai K. Nuclear export of glucocorticoid receptor is enhanced by c-Jun Nterminal kinase-mediated phosphorylation. Molecular Endocrinology (Baltimore, MD). 2002;16(10):2382–2392
  126. Davies L, Karthikeyan N, Lynch JT, Sial EA, Gkourtsa A, Demonacos C, et al. Cross talk of signaling pathways in the regulation of the glucocorticoid receptor function. Molecular Endocrinology (Baltimore, MD). 2008;22(6):1331–1344
  127. Onda K, Nagashima M, Kawakubo Y, Inoue S, Hirano T, Oka K. Mitogen-activated protein kinase kinase 1/extracellular signal regulated kinase (MEK-1/ERK) inhibitors sensitize reduced glucocorticoid response mediated by TNFalpha in human epidermal keratinocytes (HaCaT). Biochemical and Biophysical Research Communications. 2006;351(1):266–272
  128. Li LB, Goleva E, Hall CF, Ou LS, Leung DY. Superantigen-induced corticosteroid resistance of human T cells occurs through activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK-ERK) pathway. The Journal of Allergy and Clinical Immunology. 2004;114(5):1059–1069
  129. Lewis-Tuffin LJ, Cidlowski JA. The physiology of human glucocorticoid receptor beta (hGRbeta) and glucocorticoid resistance. Annals of the New York Academy of Sciences. 2006;1069:1–9
  130. Li LB, Leung DY, Hall CF, Goleva E. Divergent expression and function of glucocorticoid receptor beta in human monocytes and T cells. Journal of Leukocyte Biology. 2006;79(4):818–827
  131. Tliba O, Cidlowski JA, Amrani Y. CD38 expression is insensitive to steroid action in cells treated with tumor necrosis factor-alpha and interferongamma by a mechanism involving the up-regulation of the glucocorticoid receptor beta isoform. Molecular Pharmacology. 2006;69(2):588–596
  132. Kim SH, Kim DH, Lavender P, Seo JH, Kim YS, Park JS, et al. Repression of TNF-alpha-induced IL-8 expression by the glucocorticoid receptor-beta involves inhibition of histone H4 acetylation. Experimental & Molecular Medicine. 2009;41(5):297–306
  133. de Lange P, Koper JW, Brinkmann AO, de Jong FH, Lamberts SW. Natural variants of the beta isoform of the human glucocorticoid receptor do not alter sensitivity to glucocorticoids. Molecular and Cellular Endocrinology. 1999;153(1–2):163–168
  134. Hecht K, Carlstedt-Duke J, Stierna P, Gustafsson J, Bronnegard M, Wikstrom AC. Evidence that the beta-isoform of the human glucocorticoid receptor does not act as a physiologically significant repressor. The Journal of Biological Chemistry. 1997;272(42):26659–26664
  135. Otto C, Reichardt HM, Schutz G. Absence of glucocorticoid receptor-beta in mice. The Journal of Biological Chemistry. 1997;272(42):26665–26668
  136. Schaaf MJ, Champagne D, van Laanen IH, van Wijk DC, Meijer AH, Meijer OC, et al. Discovery of a functional glucocorticoid receptor betaisoform in zebrafish. Endocrinology. 2008;149(4):1591–1599
  137. Pace TW, Hu F, Miller AH. Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain, Behavior, and Immunity. 2007;21(1):9–19
  138. Falus A, Biro J, Rakasz E. Cytokine networks and corticosteroid receptors. Annals of the New York Academy of Sciences. 1995;762:71–77discussion 77–8
  139. Wei P, Vedeckis WV. Regulation of the glucocorticoid receptor gene by the AP-1 transcription factor. Endocrine. 1997;7(3):303–310
  140. Schaaf MJ, Cidlowski JA. AUUUA motifs in the 3’UTR of human glucocorticoid receptor alpha and beta mRNA destabilize mRNA and decrease receptor protein expression. Steroids. 2002;67(7):627–636
  141. Burnstein KL, Jewell CM, Cidlowski JA. Human glucocorticoid receptor cDNA contains sequences sufficient for receptor down-regulation. The Journal of Biological Chemistry. 1990;265(13):7284–7291
  142. Dong Y, Poellinger L, Gustafsson JA, Okret S. Regulation of glucocorticoid receptor expression: evidence for transcriptional and posttranslational mechanisms. Molecular Endocrinology (Baltimore, MD). 1988;2(12):1256–1264
  143. Kalinyak JE, Dorin RI, Hoffman AR, Perlman AJ. Tissue-specific regulation of glucocorticoid receptor mRNA by dexamethasone. The Journal of Biological Chemistry. 1987;262(22):10441–10444
  144. Rosewicz S, McDonald AR, Maddux BA, Goldfine ID, Miesfeld RL, Logsdon CD. Mechanism of glucocorticoid receptor down-regulation by glucocorticoids. The Journal of Biological Chemistry. 1988;263(6):2581–2584
  145. Vedeckis WV, Ali M, Allen HR. Regulation of glucocorticoid receptor protein and mRNA levels. Cancer Research. 1989;49(8 Suppl.):2295s–2302s
  146. Geng CD, Schwartz JR, Vedeckis WV. A conserved molecular mechanism is responsible for the auto-up-regulation of glucocorticoid receptor gene promoters. Molecular Endocrinology (Baltimore, MD). 2008;22(12):2624–2642
  147. Liu DH, Su YP, Zhang W, Lou SF, Ran XZ, Gao JS, et al. Downregulation of glucocorticoid receptors of liver cytosols and the role of the inflammatory cytokines in pathological stress in scalded rats. Burns. 2002;28(4):315–320
  148. Hutchison KA, Matic G, Meshinchi S, Bresnick EH, Pratt WB. Redox manipulation of DNA binding activity and BuGR epitope reactivity of the glucocorticoid receptor. The Journal of Biological Chemistry. 1991;266(16):10505–10509
  149. Tienrungroj W, Meshinchi S, Sanchez ER, Pratt SE, Grippo JF, Holmgren A, et al. The role of sulfhydryl groups in permitting transformation and DNA binding of the glucocorticoid receptor. The Journal of Biological Chemistry. 1987;262(15):6992–7000
  150. Sohn KC, Jang S, Choi DK, Lee YS, Yoon TJ, Jeon EK, et al. Effect of thioredoxin reductase 1 on glucocorticoid receptor activity in human outer root sheath cells. Biochemical and Biophysical Research Communications. 2007;356(3):810–815
  151. Wang HC, Zentner MD, Deng HT, Kim KJ, Wu R, Yang PC, et al. Oxidative stress disrupts glucocorticoid hormone-dependent transcription of the amiloride-sensitive epithelial sodium channel alpha-subunit in lung epithelial cells through ERK-dependent and thioredoxin-sensitive pathways. The Journal of Biological Chemistry. 2000;275(12):8600–8609
  152. Morgan MJ, Kim YS, Liu ZG. TNFalpha and reactive oxygen species in necrotic cell death. Cell Research. 2008;18(3):343–349
  153. Bodwell JE, Holbrook NJ, Munck A. Sulfhydryl-modifying reagents reversibly inhibit binding of glucocorticoid-receptor complexes to DNA-cellulose. Biochemistry. 1984;23(7):1392–1398
  154. Kitagawa H, Yamaoka I, Akimoto C, Kase I, Mezaki Y, Shimizu T, et al. A reduction state potentiates the glucocorticoid response through receptor protein stabilization. Genes to Cells. 2007;12(11):1281–1287
  155. Makino Y, Okamoto K, Yoshikawa N, Aoshima M, Hirota K, Yodoi J, et al. Thioredoxin: a redox-regulating cellular cofactor for glucocorticoid hormone action. Cross talk between endocrine control of stress response and cellular antioxidant defense system. The Journal of Clinical Investigation. 1996;98(11):2469–2477
  156. Tanaka H, Makino Y, Okamoto K, Iida T, Yan K, Yoshikawa N. Redox regulation of the glucocorticoid receptor. Antioxidants & Redox Signaling. 1999;1(4):403–423
  157. Okamoto K, Tanaka H, Ogawa H, Makino Y, Eguchi H, Hayashi S, et al. Redox-dependent regulation of nuclear import of the glucocorticoid receptor. The Journal of Biological Chemistry. 1999;274(15):10363–10371
  158. Asaba K, Iwasaki Y, Yoshida M, Asai M, Oiso Y, Murohara T, et al. Attenuation by reactive oxygen species of glucocorticoid suppression on proopiomelanocortin gene expression in pituitary corticotroph cells. Endocrinology. 2004;145(1):39–42
  159. Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell. 2005;120(5):649–661
  160. Takeda K, Matsuzawa A, Nishitoh H, Ichijo H. Roles of MAPKKK ASK1 in stress-induced cell death. Cell Structure and Function. 2003;28(1):23–29
  161. Adcock IM, Cosio B, Tsaprouni L, Barnes PJ, Ito K. Redox regulation of histone deacetylases and glucocorticoid mediated inhibition of the inflammatory response. Antioxidants & Redox Signaling. 2005;7(1–2):144–152
  162. Galigniana MD, Piwien-Pilipuk G, Assreuy J. Inhibition of glucocorticoid receptor binding by nitric oxide. Molecular Pharmacology. 1999;55(2):317–323
  163. Duma D, Silva-Santos JE, Assreuy J. Inhibition of glucocorticoid receptor binding by nitric oxide in endotoxemic rats. Critical Care Medicine. 2004;32(11):2304–2310
  164. Ji JY, Diamond SL. Exogenous nitric oxide activates the endothelial glucocorticoid receptor. Biochemical and Biophysical Research Communications. 2004;318(1):192–197
  165. Paul-Clark MJ, Roviezzo F, Flower RJ, Cirino G, Soldato PD, Adcock IM, et al. Glucocorticoid receptor nitration leads to enhanced antiinflammatory effects of novel steroid ligands. Journal of Immunology (Baltimore, MD). 2003;171(6):3245–3252
  166. Da J, Chen L, Hedenstierna G. Nitric oxide up-regulates the glucocorticoid receptor and blunts the inflammatory reaction in porcine endotoxin sepsis. Critical Care Medicine. 2007;35(1):26–32
  167. Cauwels A. Nitric oxide in shock. Kidney International. 2007;72(5):557–565
  168. Breuner CW, Orchinik M. Plasma binding proteins as mediators of corticosteroid action in vertebrates. The Journal of Endocrinology. 2002;175(1):99–112
  169. Hammond GL. Molecular properties of corticosteroid binding globulin and the sex-steroid binding proteins. Endocrine Reviews. 1990;11(1):65–79
  170. Torpy DJ, Ho JT. Value of free cortisol measurement in systemic infection. Hormone and Metabolic Research=Hormon- und Stoffwechselforschung=Hormones et metabolisme. 2007;39(6):439–444
  171. Emptoz-Bonneton A, Crave JC, LeJeune H, Brebant C, Pugeat M. Corticosteroid-binding globulin synthesis regulation by cytokines and glucocorticoids in human hepatoblastoma-derived (HepG2) cells. The Journal of Clinical Endocrinology and Metabolism. 1997;82(11):3758–3762
  172. Fleshner M, Silbert L, Deak T, Goehler LE, Martin D, Watkins LR, et al. TNF-alpha-induced corticosterone elevation but not serum protein or corticosteroid binding globulin reduction is vagally mediated. Brain Research Bulletin. 1997;44(6):701–706
  173. Draper N, Stewart PM. 11Beta-hydroxysteroid dehydrogenase and the prereceptor regulation of corticosteroid hormone action. The Journal of Endocrinology. 2005;186(2):251–271
  174. Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, et al. 11Beta-hydroxysteroid dehydrogenase type 1: a tissuespecific regulator of glucocorticoid response. Endocrine Reviews. 2004;25(5):831–866
  175. Cooper MS, Bujalska I, Rabbitt E, Walker EA, Bland R, Sheppard MC, et al. Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. Journal of Bone and Mineral Research. 2001;16(6):1037–1044
  176. Escher G, Galli I, Vishwanath BS, Frey BM, Frey FJ. Tumor necrosis factor alpha and interleukin 1beta enhance the cortisone/cortisol shuttle. The Journal of Experimental Medicine. 1997;186(2):189–198
  177. Ignatova ID, Kostadinova RM, Goldring CE, Nawrocki AR, Frey FJ, Frey BM. Tumor necrosis factor-alpha upregulates 11betahydroxysteroid dehydrogenase type 1 expression by CCAAT/enhancer binding protein-beta in HepG2 cells. American Journal of Physiology. 2009;296(2):E367–E377
  178. Ishii-Yonemoto T, Masuzaki H, Yasue S, Okada S, Kozuka C, Tanaka T, et al. Glucocorticoid reamplification within cells intensifies NF-κB and MAPK signaling and reinforces inflammation in activated preadipocytes. American Journal of Physiology. 2009;
  179. Kimura H, Li X, Torii K, Okada T, Kamiyama K, Mikami D, et al. Dexamethasone enhances basal and TNF-alpha-stimulated production of PAI-1 via the glucocorticoid receptor regardless of 11betahydroxysteroid dehydrogenase 2 status in human proximal renal tubular cells. Nephrology, Dialysis, Transplantation. 2009;24(6):1759–1765
  180. Kossintseva I, Wong S, Johnstone E, Guilbert L, Olson DM, Mitchell BF. Proinflammatory cytokines inhibit human placental 11betahydroxysteroid dehydrogenase type 2 activity through Ca2+ and cAMP pathways. American Journal of Physiology. 2006;290(2):E282–E288

PII: S1359-6101(10)00032-8

doi: 10.1016/j.cytogfr.2010.04.003

Cytokine & Growth Factor Reviews
Volume 21, Issue 4 , Pages 275-286 , August 2010

Article Tools

* Image Usage & Resolution